<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261413</url>
  </required_header>
  <id_info>
    <org_study_id>RS-001</org_study_id>
    <nct_id>NCT04261413</nct_id>
  </id_info>
  <brief_title>Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic NSCLC</brief_title>
  <official_title>A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study designed as a multicenter, open label, two-step study to determine the optimum&#xD;
      dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally&#xD;
      advanced or metastatic non-small cell lung cancer (NSCLC). The research is planned as a&#xD;
      two-step study (Phase Ia and phase Ib) and accelerated titration design (ATD) is used.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>21 days for Phase Ia and 100 days for Phase Ib</time_frame>
    <description>The maximum tolerated dose and the appropriate dose range of RS-0139 in recurrent, locally advanced or metastatic non-small cell lung cancer patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>21 days for Phase Ia and 100 days for Phase Ib</time_frame>
    <description>The incidence of dose-limiting toxicities occurring after each dose given to the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reductions or treatment interruptions</measure>
    <time_frame>21 days for Phase Ia and 100 days for Phase Ib</time_frame>
    <description>Dose reductions or treatment interruptions due to the possible adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>RS-0139</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be only RS-0139 arm in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RS-0139</intervention_name>
    <description>RS-0139 will be administered for the indication of NSCLC.</description>
    <arm_group_label>RS-0139</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have consented for the participation to the trial.&#xD;
&#xD;
          -  Patients of both sexes aged between 18-75 years.&#xD;
&#xD;
          -  Patients who have biopsy material prior to the participation in order to confirm the&#xD;
             expression of integrin αvβ6 (for Phase Ib only).&#xD;
&#xD;
          -  Patients with stage IIIB or IV NSCLC and measurable disease by Response Evaluation&#xD;
             Criteria in Solid Tumors and availability of at least one measurable tumor focus under&#xD;
             RECIST v.1.1 criteria.&#xD;
&#xD;
          -  Patients with NSCLC who progressed after standard therapy options consisting of&#xD;
             chemotherapy and/or immunotherapy.&#xD;
&#xD;
          -  Patients who completed the previous treatments 21 days before the first dose of the&#xD;
             study drug.&#xD;
&#xD;
          -  Patients who have at least three months of life expectancy.&#xD;
&#xD;
          -  Patients with ECOG performance score 0-1&#xD;
&#xD;
          -  Patients with the following laboratory results:&#xD;
&#xD;
               -  Hemoglobin ≥10 mg/dl&#xD;
&#xD;
               -  Neutrophil ≥1,500/µL&#xD;
&#xD;
               -  Platelet ≥100,000/µL&#xD;
&#xD;
               -  Creatinine ≤1.5xULN or creatinine clearance ≥60mL/sec/1.73m2&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5xULN&#xD;
&#xD;
               -  AST/ALT ≤2.5xULN; for patients who have confirmed liver metastasis: AST/ALT&#xD;
                  ≤5xULN.&#xD;
&#xD;
               -  Prothrombin time ≤1.5xULN (in case of no anticoagulant treatment).&#xD;
&#xD;
               -  Normal levels of serum magnesium and potassium concentrations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have active and/or uncontrolled central nervous system (CNS) metastasis.&#xD;
&#xD;
          -  Patients who have pulmonary carcinosarcoma.&#xD;
&#xD;
          -  Patients who have presence of small cell lung cancer components.&#xD;
&#xD;
          -  Patients who have interstitial lung disease or interstitial pneumonia.&#xD;
&#xD;
          -  Patients who have serious cardiac dysfunction.&#xD;
&#xD;
          -  Patients who have insufficient target organ function.&#xD;
&#xD;
          -  Patients who experienced Grade 3 or higher toxicity related to the previous docetaxel&#xD;
             treatment.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patients who are enrolled in a clinical trial.&#xD;
&#xD;
          -  Patients who have serious medical conditions such as uncontrolled infection or&#xD;
             untreated wound.&#xD;
&#xD;
          -  Patients who have bone marrow transplantation history.&#xD;
&#xD;
          -  Patients who have hypersensitivity to docetaxel and/or similar medicines.&#xD;
&#xD;
          -  Patients who, in the judgment of the Investigator, are likely to be non-compliant or&#xD;
             unable to cooperate.&#xD;
&#xD;
          -  Patients who cannot be contacted in case of emergency.&#xD;
&#xD;
          -  Patients who are the investigator or sub-investigator, research assistant, pharmacist,&#xD;
             study coordinator or other staff directly involved in conducting the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gulsah Nomak</last_name>
    <phone>00905333020180</phone>
    <email>gulsahnomak@mispharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sena Nomak</last_name>
    <phone>00905307606762</phone>
    <email>sn@rsresearch.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Selim Şentürk</last_name>
      <email>drselim32@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koç University Hospital Phase I Center</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakan S Orer</last_name>
      <email>horer@ku.edu.tr</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer, chemotherapy, targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

